As a student, Scott Rocklage was blessed to enter the orbit of a yet-to-be-named Nobel Prize winner and a lot of ‘fun guys and gals’ with super-sized brains and ambitions, not unlike his own.
The rocket-ship which brought him into this orbit was MIT, a significant rock along an educational footpath that included Bachelor degrees in science and chemistry from the University of California, also the place where Rocklage earned his PhD in chemistry.
It’s where, more than forty years later, Sexagenarian, Dr. Scott Rocklage PhD, would offer gratitude for the mentorship and scholarship afforded him while at MIT, along with a gift of monies to fund lab space for future brainiacs with outsize visions.
Of course, MIT has produced its share of whiz-kids, including Nobel laureate, Richard R. Schrock, who worked in the Chemistry department during Rocklage’s time at school and Rocklage himself, who leveraged his earned-at-MIT know-how into top-tier positions at a dizzying array of prominent companies. Learn more about Scott Rocklage: http://5amventures.com/team/scott-m-rocklage-phd/ and http://chemistry.mit.edu/scott-rocklage-phd-2-and-his-wife-patty-are-celebrated-their-major-gift
A wide-scale, though not-exhaustive, list of places where Rocklage has served, whether as director, board member, chief executive officer, president, co-president, board chairman, managing partner, or in some other leadership capacity of note, includes, Epirus Bio-pharmaceuticals, Amersham Health, Ilypsa Inc., Cubist Pharmaceuticals, Nycomed Interventional Inc., Novira Therapeutics, Rennovia Inc., MDS Poteomics, Inc. Semprus BioSciences Corp ., Relypsa Inc., Pulmatrix, Mikana Therapeutics, Cidara Therapeutics and VBI Vaccines Inc.
Highly significant, although not on the list, is the company Scott Rocklage currently helms, managing partner, since 2004, 5AM Venture Management LLC.
Forward-thinking in its policy of seeking emergent medical technologies, mentoring them, even going so far at times as taking limited, operational roles within them, Venture continuously retools its science portfolio, using a diverse blend of professionals, from the areas of business, law and medicine.
As its name suggests, 5AM Venture Management is often among the earliest to spot exciting new trends with disease-fighting potential. Currently on the company’s list of trends to be excited about is genotype research, with its cancer-predicting potential.
Not surprisingly, a man with trend-spotting acumen and health management skill, honed over decades, doesn’t mine from one area of endeavor. Besides his business accomplishments, Rocklage has used his leadership skills to steer, from application to approval, three drugs.
30 patients exist due to his scientific prowess. He’s published more than 100 times, in peer-reviewed publications. At 61, it’s safe to say the self-described ‘accomplishment-junkie’ is far from done.